MedWatch

Biomarin projects 2022 Voxzogo sales of USD 115m

US-based Biomarin brought its dwarfism drug Voxzogo to the market in 2021, and the company has great expectations for the drug in 2022.

Biomarin's Voxzogo is designed to treat achondroplasia, also known as dwarfism | Photo: Anders Rye Skjoldjensen

US-based biotech firm Biomarin has released its full-year financial report on Wednesday, and in connection with the report came the company’s 2022 sales prognosis for potential cash cow Voxzogo.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs